IL302329A - A method for treating cancers using alkyne-modified quinsoline derivatives - Google Patents
A method for treating cancers using alkyne-modified quinsoline derivativesInfo
- Publication number
- IL302329A IL302329A IL302329A IL30232923A IL302329A IL 302329 A IL302329 A IL 302329A IL 302329 A IL302329 A IL 302329A IL 30232923 A IL30232923 A IL 30232923A IL 302329 A IL302329 A IL 302329A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- egfr
- cancer
- pharmaceutically acceptable
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108645P | 2020-11-02 | 2020-11-02 | |
| US202163166045P | 2021-03-25 | 2021-03-25 | |
| US202163190067P | 2021-05-18 | 2021-05-18 | |
| US202163218717P | 2021-07-06 | 2021-07-06 | |
| US202163237782P | 2021-08-27 | 2021-08-27 | |
| US202163244540P | 2021-09-15 | 2021-09-15 | |
| PCT/US2021/057724 WO2022094464A1 (en) | 2020-11-02 | 2021-11-02 | Method of treating cancers with alkyne substituted quinazoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL302329A true IL302329A (en) | 2023-06-01 |
Family
ID=78819639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL302329A IL302329A (en) | 2020-11-02 | 2021-11-02 | A method for treating cancers using alkyne-modified quinsoline derivatives |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240075042A1 (https=) |
| EP (1) | EP4236954A1 (https=) |
| JP (1) | JP2023548055A (https=) |
| KR (1) | KR20230093429A (https=) |
| AU (1) | AU2021368798A1 (https=) |
| CA (1) | CA3195473A1 (https=) |
| IL (1) | IL302329A (https=) |
| MX (1) | MX2023004998A (https=) |
| TW (1) | TWI910256B (https=) |
| WO (1) | WO2022094464A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020328598A1 (en) | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| CA3231697A1 (en) * | 2021-09-21 | 2023-03-30 | Black Diamond Therapeutics, Inc. | Polymorphs as erbb inhibitors |
| WO2025038731A1 (en) * | 2023-08-15 | 2025-02-20 | Black Diamond Therapeutics, Inc. | Method of treating cancers with alkyne substituted quinazoline derivatives |
| WO2025128831A1 (en) * | 2023-12-13 | 2025-06-19 | Black Diamond Therapeutics, Inc. | Combinations comprising alkyne substituted quinazoline derivatives and their use in the treatment of cancer |
| WO2025137421A1 (en) * | 2023-12-21 | 2025-06-26 | Black Diamond Therapeutics, Inc. | Compositions comprising alkyne substituted quinazoline derivatives and related uses |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012122058A2 (en) * | 2011-03-04 | 2012-09-13 | Newgen Therapeutics, Inc. | Alkyne substituted quinazoline compound and methods of use |
| US20180193274A1 (en) * | 2014-12-24 | 2018-07-12 | Principia Biopharma Inc. | Compositions for ileo-jejunal drug delivery |
| JP2022502495A (ja) * | 2018-09-25 | 2022-01-11 | ブラック ダイアモンド セラピューティクス，インコーポレイティド | チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用 |
| AU2020328598A1 (en) * | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
-
2021
- 2021-11-02 US US18/034,749 patent/US20240075042A1/en active Pending
- 2021-11-02 MX MX2023004998A patent/MX2023004998A/es unknown
- 2021-11-02 KR KR1020237013278A patent/KR20230093429A/ko active Pending
- 2021-11-02 EP EP21816235.2A patent/EP4236954A1/en active Pending
- 2021-11-02 IL IL302329A patent/IL302329A/en unknown
- 2021-11-02 JP JP2023524708A patent/JP2023548055A/ja active Pending
- 2021-11-02 AU AU2021368798A patent/AU2021368798A1/en active Pending
- 2021-11-02 WO PCT/US2021/057724 patent/WO2022094464A1/en not_active Ceased
- 2021-11-02 CA CA3195473A patent/CA3195473A1/en active Pending
- 2021-11-02 TW TW110140833A patent/TWI910256B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI910256B (zh) | 2026-01-01 |
| AU2021368798A9 (en) | 2023-07-06 |
| KR20230093429A (ko) | 2023-06-27 |
| MX2023004998A (es) | 2023-05-12 |
| EP4236954A1 (en) | 2023-09-06 |
| WO2022094464A1 (en) | 2022-05-05 |
| US20240075042A1 (en) | 2024-03-07 |
| CA3195473A1 (en) | 2022-05-05 |
| JP2023548055A (ja) | 2023-11-15 |
| AU2021368798A1 (en) | 2023-05-18 |
| TW202235083A (zh) | 2022-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL302329A (en) | A method for treating cancers using alkyne-modified quinsoline derivatives | |
| KR102857219B1 (ko) | 암의 치료 또는 예방용 의약 | |
| JP5778735B2 (ja) | Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して耐性を獲得した疾患を治療するためのピリミジン誘導体の使用 | |
| TW202128174A (zh) | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 | |
| EP3226869A1 (en) | Kinase inhibitor prodrug for the treatment of cancer | |
| US20220041613A1 (en) | Tyrosine kinase inhibitor compositions, methods of making and methods of use | |
| JP2026048890A (ja) | 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ | |
| WO2025038731A1 (en) | Method of treating cancers with alkyne substituted quinazoline derivatives | |
| CN116710096A (zh) | 用炔取代的喹唑啉衍生物治疗癌症的方法 | |
| US20230321087A1 (en) | Fgfr inhibitor combination therapies | |
| KR20260053328A (ko) | 알킨 치환된 퀴나졸린 유도체를 이용한 암 치료 방법 | |
| EP4534085A1 (en) | Compounds for use in methods of treating cancer | |
| WO2026064728A1 (en) | Method of treating cancers with alkyne substituted quinazoline derivatives | |
| TWI920018B (zh) | 抗ｈｅｒ３抗體-藥物結合物用於治療ｈｅｒ３突變癌之醫藥的用途 | |
| CN118791477A (zh) | Aak1抑制剂及其用途 | |
| TW201217341A (en) | Receptor-type kinase modulator and methods of treating polycystic kidney disease |